Biodexa says that Its MTX110 May Extend Life Expectancy Against Aggressive Brain Cancers

DENVER, Colo., Mar 28, 2024 ( Biodexa Pharmaceuticals (NASDAQ:BDRX) stated, this morning, that it’s developing MTX110 for the treatment of Diffuse Midline Glioma (DMG) in pediatric patients and for Recurrent Glioblastoma (rGBM) in adults, and early MTX110 trials in both cancers show promise in extending survival rates beyond those reported in previously published studies for those two aggressive brain cancers with universally poor prognoses.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to for disclaimer information.

24/7 Market News
[email protected]

Related news for (NASDAQ:BDRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.